Sign in to continue:

Wednesday, May 6th, 2026

Guerrilla RF Reports 48% Year-Over-Year Revenue Growth to $6.5 Million in Q1 2026 Results





Guerrilla RF Reports Q1 2026 Results: Revenue Surges, Operating Loss Narrows, and Backlog Expands

Guerrilla RF Reports Q1 2026 Results: Revenue Surges, Operating Loss Narrows, and Backlog Expands

Key Highlights from Q1 2026 Earnings Release

  • Revenue up 48% year-over-year to \$6.5 million
  • Gross margin expands to 69.9%, an increase of ~880 basis points YoY
  • Operating loss narrows to near breakeven at (\$46) thousand
  • Net income turns positive at \$1.1 million, compared to a net loss of \$3.5 million in Q1 2025
  • Product backlog grows to \$8.8 million
  • Disciplined cost management reduces operating expenses by 22%
  • Cash position of \$3.2 million as of March 31, 2026
  • Company reiterates focus on achieving full-year operating profitability in 2026

Detailed Financial and Operational Review

Revenue and Gross Profit

Guerrilla RF, Inc. delivered robust growth in the first quarter of 2026, with total revenue rising 48% year-over-year to \$6.5 million. This performance was primarily driven by a remarkable 207% surge in catalog revenue, reflecting the success of the company’s product strategy and strong demand for its offerings.

Gross profit increased 69% year-over-year to \$4.5 million. The company achieved a significant expansion in gross profit margin, which rose by 880 basis points to 69.9%, supported by higher sales volumes and a more favorable product mix. This outpaced the 14% increase in direct product costs, highlighting the positive operating leverage within the business model.

Profitability and Operating Expenses

A key milestone this quarter was the company’s near achievement of operating breakeven. Operating loss narrowed sharply to just (\$46) thousand, a substantial improvement from prior periods. On a net basis, the company swung to a net income of \$1.1 million, compared to a net loss of \$3.5 million in the first quarter of 2025. Earnings per share reached \$0.06, up from a loss of (\$0.34) per share in the previous year.

The company’s disciplined approach to cost control yielded a 22% reduction in operating expenses, which totaled \$4.6 million, down from \$5.8 million in the prior-year period. This reflects carefully managed expenditure across all business functions, further supporting improved profitability.

Backlog, Product Portfolio, and Liquidity

Guerrilla RF’s product backlog stood at \$8.8 million at the end of Q1 2026, up from \$6.7 million a year ago. This robust backlog provides good revenue visibility and underpins management’s confidence in delivering future growth. The company released 8 new products in the quarter, bringing the total number of production-released products to 183. Notably, 83 of these products have now generated lifetime revenue exceeding \$100,000 each, underscoring the strength and reach of the company’s catalog.

As of March 31, 2026, Guerrilla RF reported a cash position of \$3.2 million, providing a foundation for ongoing operations and future investments.

Management Commentary and Outlook

“The first quarter of 2026 demonstrates the financial leverage in our model,” said CFO Mike John-Williams. “Revenue grew 48% while direct product costs increased only 14%, expanding gross margin by nearly 880 basis points. At the same time, disciplined spending reduced operating expenses by 22%. We believe we are well positioned for continued growth and profitability.”

Management remains focused on converting design wins into recurring revenue, expanding margins, and achieving full-year operating profitability in 2026. The improved cost structure and expanded product backlog underscore the company’s positive trajectory and its commitment to delivering shareholder value.

Matters of Interest for Shareholders

  • Return to profitability: The swing to net income and near-breakeven operating results are likely to be viewed positively by investors and could be share price accretive.
  • Significant revenue and margin growth: Substantial improvement in both top-line growth and gross profitability suggests successful execution of the company’s strategy and strengthens the investment case.
  • Growing product backlog: The \$8.8 million backlog provides visibility into future revenue streams and may drive further investor optimism.
  • Operating leverage and cost discipline: Operating expense reductions amid rapid sales growth highlight a scalable business model, potentially enhancing valuation multiples.
  • Outlook for 2026: The company’s reaffirmed goal of full-year operating profitability represents a key milestone and potential catalyst for re-rating the stock.

Potential Price Sensitive Information

  • Return to net profitability and breakeven operating results are significant financial milestones.
  • Exceptional YoY revenue and margin expansion may alter investor expectations about the company’s growth trajectory.
  • Substantial product backlog indicates strong demand pipeline.
  • Management’s guidance for full-year profitability may drive share price appreciation if achieved.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with their financial advisors before making any investment decisions. Past performance is not indicative of future results. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated.




View Guerrilla RF, Inc. Historical chart here



CitroTech Inc. 2025 Annual Report: Sustainable Fire Inhibitor Business, Financial Performance, and Key Risks

CitroTech Inc. 2025 Annual Report – Key Highlights and Inves...

Getty Realty Corp. Underwriting Agreement and Forward Confirmation Details for 2026 Public Offering

Getty Realty Corp. Announces Public Offering of Common Stock...

AN2 Therapeutics Secures $40 Million in Private Placement Financing to Advance Boron-Based Drug Pipeline

AN2 Therapeutics Announces \$40 Million Private Placement Fi...

   Ad

Join Our Investing Seminar

Limited seats available — Reserve your spot today